(PLXS) Plexus - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7291321005
Stock: Electronics, Manufacturing, Aerospace, Healthcare, Industrial
Total Rating 66
Risk 99
Buy Signal 0.96
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 43.7% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.05 |
| Alpha | 26.23 |
| Character TTM | |
|---|---|
| Beta | 1.256 |
| Beta Downside | 1.387 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.92% |
| CAGR/Max DD | 0.80 |
Description: PLXS Plexus January 12, 2026
Plexus Corp. (NASDAQ: PLXS) is a global provider of electronic manufacturing services (EMS), delivering design, development, supply-chain management, new-product introduction, and sustaining production across the United States, Asia-Pacific, Europe, the Middle East, and Africa.
The company’s end-market focus includes aerospace & defense, healthcare & life sciences, and industrial/commercial sectors, positioning it to benefit from rising defense budgets (U.S. defense spending grew ~3.5% YoY in FY2023) and the accelerating adoption of medical-device electronics.
Key operating metrics from the most recent fiscal year show revenue of approximately $2.2 billion, an adjusted EBITDA margin near 7.5%, and a backlog of roughly $1.1 billion-indicating a solid order pipeline but also exposing the firm to the ongoing semiconductor supply constraints that have pressured EMS margins industry-wide.
Strategically, Plexus is pursuing nearshoring initiatives to mitigate supply-chain risk and capture higher-margin work in the U.S., a trend reinforced by recent policy incentives for domestic electronics manufacturing.
For a deeper, data-driven look at PLXS’s valuation metrics, you might explore ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 176.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -9.05 > 1.0 |
| NWC/Revenue: 22.12% < 20% (prev 20.79%; Δ 1.34% < -1%) |
| CFO/TA 0.06 > 3% & CFO 195.6m > Net Income 176.8m |
| Net Debt (-63.5m) to EBITDA (264.9m): -0.24 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.3m) vs 12m ago -1.49% < -2% |
| Gross Margin: 9.98% > 18% (prev 0.10%; Δ 988.4% > 0.5%) |
| Asset Turnover: 131.9% > 50% (prev 128.8%; Δ 3.15% > 0%) |
| Interest Coverage Ratio: 13.95 > 6 (EBITDA TTM 264.9m / Interest Expense TTM 10.9m) |
Altman Z'' 5.56
| A: 0.29 (Total Current Assets 2.46b - Total Current Liabilities 1.54b) / Total Assets 3.19b |
| B: 0.64 (Retained Earnings 2.04b / Total Assets 3.19b) |
| C: 0.05 (EBIT TTM 152.6m / Avg Total Assets 3.13b) |
| D: 1.21 (Book Value of Equity 2.06b / Total Liabilities 1.70b) |
| Altman-Z'' Score: 5.56 = AAA |
Beneish M -3.00
| DSRI: 0.90 (Receivables 679.7m/725.6m, Revenue 4.13b/3.95b) |
| GMI: 0.99 (GM 9.98% / 9.89%) |
| AQI: 1.15 (AQ_t 0.04 / AQ_t-1 0.03) |
| SGI: 1.04 (Revenue 4.13b / 3.95b) |
| TATA: -0.01 (NI 176.8m - CFO 195.6m) / TA 3.19b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = AA |
What is the price of PLXS shares?
As of February 08, 2026, the stock is trading at USD 206.22 with a total of 503,420 shares traded.
Over the past week, the price has changed by +3.46%, over one month by +31.24%, over three months by +43.71% and over the past year by +45.28%.
Over the past week, the price has changed by +3.46%, over one month by +31.24%, over three months by +43.71% and over the past year by +45.28%.
Is PLXS a buy, sell or hold?
Plexus has received a consensus analysts rating of 3.80.
Therefor, it is recommend to hold PLXS.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PLXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 191.2 | -7.3% |
| Analysts Target Price | 191.2 | -7.3% |
| ValueRay Target Price | 259.8 | 26% |
PLXS Fundamental Data Overview January 31, 2026
P/E Trailing = 30.7788
P/S = 1.282
P/B = 3.5716
P/EG = 1.61
Revenue TTM = 4.13b USD
EBIT TTM = 152.6m USD
EBITDA TTM = 264.9m USD
Long Term Debt = 92.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 66.8m USD (from shortTermDebt, last quarter)
Debt = 185.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.5m USD (from netDebt column, last quarter)
Enterprise Value = 5.23b USD (5.29b + Debt 185.3m - CCE 248.8m)
Interest Coverage Ratio = 13.95 (Ebit TTM 152.6m / Interest Expense TTM 10.9m)
EV/FCF = 41.20x (Enterprise Value 5.23b / FCF TTM 126.9m)
FCF Yield = 2.43% (FCF TTM 126.9m / Enterprise Value 5.23b)
FCF Margin = 3.07% (FCF TTM 126.9m / Revenue TTM 4.13b)
Net Margin = 4.28% (Net Income TTM 176.8m / Revenue TTM 4.13b)
Gross Margin = 9.98% ((Revenue TTM 4.13b - Cost of Revenue TTM 3.71b) / Revenue TTM)
Gross Margin QoQ = 9.92% (prev 9.90%)
Tobins Q-Ratio = 1.64 (Enterprise Value 5.23b / Total Assets 3.19b)
Interest Expense / Debt = 1.56% (Interest Expense 2.89m / Debt 185.3m)
Taxrate = 19.30% (9.85m / 51.0m)
NOPAT = 123.1m (EBIT 152.6m * (1 - 19.30%))
Current Ratio = 1.59 (Total Current Assets 2.46b / Total Current Liabilities 1.54b)
Debt / Equity = 0.13 (Debt 185.3m / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = -0.24 (Net Debt -63.5m / EBITDA 264.9m)
Debt / FCF = -0.50 (Net Debt -63.5m / FCF TTM 126.9m)
Total Stockholder Equity = 1.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.65% (Net Income 176.8m / Total Assets 3.19b)
RoE = 12.39% (Net Income TTM 176.8m / Total Stockholder Equity 1.43b)
RoCE = 10.05% (EBIT 152.6m / Capital Employed (Equity 1.43b + L.T.Debt 92.0m))
RoIC = 7.83% (NOPAT 123.1m / Invested Capital 1.57b)
WACC = 10.23% (E(5.29b)/V(5.48b) * Re(10.54%) + D(185.3m)/V(5.48b) * Rd(1.56%) * (1-Tc(0.19)))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.19%
[DCF Debug] Terminal Value 65.50% ; FCFF base≈236.2m ; Y1≈186.5m ; Y5≈123.1m
Fair Price DCF = 63.00 (EV 1.62b - Net Debt -63.5m = Equity 1.69b / Shares 26.8m; r=10.23% [WACC]; 5y FCF grow -25.11% → 2.90% )
EPS Correlation: 57.33 | EPS CAGR: 18.23% | SUE: 0.41 | # QB: 0
Revenue Correlation: 11.83 | Revenue CAGR: 5.07% | SUE: -0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.83 | Chg30d=+0.075 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=7.48 | Chg30d=+0.107 | Revisions Net=-4 | Growth EPS=+0.6% | Growth Revenue=+10.7%
EPS next Year (2027-09-30): EPS=8.45 | Chg30d=+0.253 | Revisions Net=+0 | Growth EPS=+13.0% | Growth Revenue=+7.7%
P/S = 1.282
P/B = 3.5716
P/EG = 1.61
Revenue TTM = 4.13b USD
EBIT TTM = 152.6m USD
EBITDA TTM = 264.9m USD
Long Term Debt = 92.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 66.8m USD (from shortTermDebt, last quarter)
Debt = 185.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.5m USD (from netDebt column, last quarter)
Enterprise Value = 5.23b USD (5.29b + Debt 185.3m - CCE 248.8m)
Interest Coverage Ratio = 13.95 (Ebit TTM 152.6m / Interest Expense TTM 10.9m)
EV/FCF = 41.20x (Enterprise Value 5.23b / FCF TTM 126.9m)
FCF Yield = 2.43% (FCF TTM 126.9m / Enterprise Value 5.23b)
FCF Margin = 3.07% (FCF TTM 126.9m / Revenue TTM 4.13b)
Net Margin = 4.28% (Net Income TTM 176.8m / Revenue TTM 4.13b)
Gross Margin = 9.98% ((Revenue TTM 4.13b - Cost of Revenue TTM 3.71b) / Revenue TTM)
Gross Margin QoQ = 9.92% (prev 9.90%)
Tobins Q-Ratio = 1.64 (Enterprise Value 5.23b / Total Assets 3.19b)
Interest Expense / Debt = 1.56% (Interest Expense 2.89m / Debt 185.3m)
Taxrate = 19.30% (9.85m / 51.0m)
NOPAT = 123.1m (EBIT 152.6m * (1 - 19.30%))
Current Ratio = 1.59 (Total Current Assets 2.46b / Total Current Liabilities 1.54b)
Debt / Equity = 0.13 (Debt 185.3m / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = -0.24 (Net Debt -63.5m / EBITDA 264.9m)
Debt / FCF = -0.50 (Net Debt -63.5m / FCF TTM 126.9m)
Total Stockholder Equity = 1.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.65% (Net Income 176.8m / Total Assets 3.19b)
RoE = 12.39% (Net Income TTM 176.8m / Total Stockholder Equity 1.43b)
RoCE = 10.05% (EBIT 152.6m / Capital Employed (Equity 1.43b + L.T.Debt 92.0m))
RoIC = 7.83% (NOPAT 123.1m / Invested Capital 1.57b)
WACC = 10.23% (E(5.29b)/V(5.48b) * Re(10.54%) + D(185.3m)/V(5.48b) * Rd(1.56%) * (1-Tc(0.19)))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.19%
[DCF Debug] Terminal Value 65.50% ; FCFF base≈236.2m ; Y1≈186.5m ; Y5≈123.1m
Fair Price DCF = 63.00 (EV 1.62b - Net Debt -63.5m = Equity 1.69b / Shares 26.8m; r=10.23% [WACC]; 5y FCF grow -25.11% → 2.90% )
EPS Correlation: 57.33 | EPS CAGR: 18.23% | SUE: 0.41 | # QB: 0
Revenue Correlation: 11.83 | Revenue CAGR: 5.07% | SUE: -0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.83 | Chg30d=+0.075 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=7.48 | Chg30d=+0.107 | Revisions Net=-4 | Growth EPS=+0.6% | Growth Revenue=+10.7%
EPS next Year (2027-09-30): EPS=8.45 | Chg30d=+0.253 | Revisions Net=+0 | Growth EPS=+13.0% | Growth Revenue=+7.7%